Free Trial
NASDAQ:SRRK

Scholar Rock Q4 2023 Earnings Report

Scholar Rock logo
$31.95 +0.55 (+1.75%)
Closing price 04:00 PM Eastern
Extended Trading
$32.78 +0.82 (+2.58%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Scholar Rock EPS Results

Actual EPS
-$0.50
Consensus EPS
-$0.49
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Scholar Rock Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Scholar Rock Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Tuesday, March 19, 2024
Conference Call Time
8:00AM ET

Scholar Rock Earnings Headlines

Scholar Rock (NASDAQ:SRRK) Trading Down 10.2% on Disappointing Earnings
Scholar Rock (NASDAQ:SRRK) Shares Gap Down on Disappointing Earnings
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
Why Scholar Rock Stock Wilted on Wednesday
See More Scholar Rock Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scholar Rock? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scholar Rock and other key companies, straight to your email.

About Scholar Rock

Scholar Rock (NASDAQ:SRRK), a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

View Scholar Rock Profile

More Earnings Resources from MarketBeat